nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—sarcoma—ocular cancer	0.635	1	CtDrD
Mitoxantrone—ABCC1—Dactinomycin—ocular cancer	0.124	0.424	CbGbCtD
Mitoxantrone—ABCG2—Dactinomycin—ocular cancer	0.0827	0.284	CbGbCtD
Mitoxantrone—ABCG2—Carboplatin—ocular cancer	0.0556	0.191	CbGbCtD
Mitoxantrone—ABCB1—Dactinomycin—ocular cancer	0.0298	0.102	CbGbCtD
Mitoxantrone—Extravasation—Carboplatin—ocular cancer	0.000763	0.0985	CcSEcCtD
Mitoxantrone—Phlebitis—Carboplatin—ocular cancer	0.000561	0.0724	CcSEcCtD
Mitoxantrone—Myelosuppression—Dactinomycin—ocular cancer	0.000527	0.0681	CcSEcCtD
Mitoxantrone—Febrile neutropenia—Dactinomycin—ocular cancer	0.000411	0.0531	CcSEcCtD
Mitoxantrone—Necrosis—Dactinomycin—ocular cancer	0.000315	0.0407	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CCND3—ocular cancer	0.0003	0.00459	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—MYC—ocular cancer	0.000293	0.00447	CbGpPWpGaD
Mitoxantrone—Extravasation—Dactinomycin—ocular cancer	0.000283	0.0366	CcSEcCtD
Mitoxantrone—PIM1—C-MYB transcription factor network—MYC—ocular cancer	0.000279	0.00426	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—HDAC1—ocular cancer	0.000273	0.00418	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—MYC—ocular cancer	0.000272	0.00415	CbGpPWpGaD
Mitoxantrone—Hypocalcaemia—Dactinomycin—ocular cancer	0.00027	0.0349	CcSEcCtD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—ID2—ocular cancer	0.000267	0.00408	CbGpPWpGaD
Mitoxantrone—Ulcer—Dactinomycin—ocular cancer	0.000261	0.0337	CcSEcCtD
Mitoxantrone—BTK—EPO signaling pathway—HRAS—ocular cancer	0.000255	0.0039	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—E2F1—ocular cancer	0.000251	0.00383	CbGpPWpGaD
Mitoxantrone—PIM1—Validated targets of C-MYC transcriptional activation—TP53—ocular cancer	0.00024	0.00367	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—MYC—ocular cancer	0.000239	0.00365	CbGpPWpGaD
Mitoxantrone—Infection—Carboplatin—ocular cancer	0.000236	0.0305	CcSEcCtD
Mitoxantrone—BTK—Kit receptor signaling pathway—EP300—ocular cancer	0.000229	0.00349	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—E2F1—ocular cancer	0.000225	0.00344	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDK6—ocular cancer	0.000224	0.00342	CbGpPWpGaD
Mitoxantrone—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—ocular cancer	0.000222	0.0034	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CCND3—ocular cancer	0.000222	0.0034	CbGpPWpGaD
Mitoxantrone—PIM1—C-MYB transcription factor network—HRAS—ocular cancer	0.000219	0.00334	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—MYC—ocular cancer	0.000217	0.00331	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—CDK2—ocular cancer	0.000216	0.0033	CbGpPWpGaD
Mitoxantrone—Sepsis—Dactinomycin—ocular cancer	0.000214	0.0277	CcSEcCtD
Mitoxantrone—BTK—FAS (CD95) signaling pathway—AKT1—ocular cancer	0.00021	0.00321	CbGpPWpGaD
Mitoxantrone—Phlebitis—Dactinomycin—ocular cancer	0.000208	0.0269	CcSEcCtD
Mitoxantrone—Pain—Carboplatin—ocular cancer	0.000203	0.0262	CcSEcCtD
Mitoxantrone—BTK—Class I PI3K signaling events—HRAS—ocular cancer	0.000194	0.00297	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CDK2—ocular cancer	0.000194	0.00296	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CCND2—ocular cancer	0.000192	0.00294	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—HDAC1—ocular cancer	0.000192	0.00294	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—AKT1—ocular cancer	0.000188	0.00288	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN2C—ocular cancer	0.000188	0.00288	CbGpPWpGaD
Mitoxantrone—Body temperature increased—Carboplatin—ocular cancer	0.000188	0.0242	CcSEcCtD
Mitoxantrone—PIM1—Ectoderm Differentiation—MYC—ocular cancer	0.000187	0.00286	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—ocular cancer	0.000183	0.0028	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—TP53—ocular cancer	0.000178	0.00272	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—RB1—ocular cancer	0.000178	0.00271	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDKN2B—ocular cancer	0.000172	0.00263	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN2C—ocular cancer	0.000168	0.00257	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—GNA11—ocular cancer	0.000167	0.00255	CbGpPWpGaD
Mitoxantrone—BTK—TSLP Signaling Pathway—AKT1—ocular cancer	0.000166	0.00253	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—ocular cancer	0.000166	0.00253	CbGpPWpGaD
Mitoxantrone—Aspartate aminotransferase increased—Dactinomycin—ocular cancer	0.000161	0.0209	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—RB1—ocular cancer	0.000159	0.00243	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—E2F1—ocular cancer	0.000158	0.00242	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—E2F5—ocular cancer	0.000157	0.0024	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—HRAS—ocular cancer	0.000156	0.00239	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—GNAQ—ocular cancer	0.000155	0.00237	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—E2F4—ocular cancer	0.000154	0.00235	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MYBL2—ocular cancer	0.000154	0.00235	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—HRAS—ocular cancer	0.000152	0.00233	CbGpPWpGaD
Mitoxantrone—CYP1B1—Tryptophan metabolism—MDM2—ocular cancer	0.000151	0.00231	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—RBL1—ocular cancer	0.000151	0.0023	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—E2F2—ocular cancer	0.000151	0.0023	CbGpPWpGaD
Mitoxantrone—Pancytopenia—Dactinomycin—ocular cancer	0.000147	0.019	CcSEcCtD
Mitoxantrone—Neutropenia—Dactinomycin—ocular cancer	0.000145	0.0187	CcSEcCtD
Mitoxantrone—BTK—BCR signaling pathway—HRAS—ocular cancer	0.000141	0.00216	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-2-alpha transcription factor network—EP300—ocular cancer	0.000141	0.00215	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—E2F5—ocular cancer	0.00014	0.00214	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—HDAC1—ocular cancer	0.00014	0.00214	CbGpPWpGaD
Mitoxantrone—Pneumonia—Dactinomycin—ocular cancer	0.000139	0.018	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—RBL2—ocular cancer	0.000138	0.00211	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ocular cancer	0.000138	0.00211	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—CDKN1B—ocular cancer	0.000138	0.00211	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—AKT1—ocular cancer	0.000138	0.00211	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—E2F4—ocular cancer	0.000137	0.0021	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MYBL2—ocular cancer	0.000137	0.0021	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDK2—ocular cancer	0.000136	0.00208	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—ocular cancer	0.000136	0.00208	CbGpPWpGaD
Mitoxantrone—Stomatitis—Dactinomycin—ocular cancer	0.000135	0.0174	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—RBL1—ocular cancer	0.000135	0.00206	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—E2F2—ocular cancer	0.000135	0.00206	CbGpPWpGaD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—AKT1—ocular cancer	0.000134	0.00206	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—MYC—ocular cancer	0.000134	0.00204	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—E2F3—ocular cancer	0.000131	0.002	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—RBBP4—ocular cancer	0.000131	0.002	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	0.000131	0.002	CbGpPWpGaD
Mitoxantrone—Agranulocytosis—Dactinomycin—ocular cancer	0.000129	0.0167	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDK4—ocular cancer	0.000129	0.00197	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—CDKN1A—ocular cancer	0.000128	0.00195	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—MDM2—ocular cancer	0.000126	0.00192	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—AKT1—ocular cancer	0.000125	0.00191	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDC25A—ocular cancer	0.000124	0.0019	CbGpPWpGaD
Mitoxantrone—Hepatitis—Dactinomycin—ocular cancer	0.000124	0.016	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—ocular cancer	0.000124	0.0019	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—RBL2—ocular cancer	0.000124	0.00189	CbGpPWpGaD
Mitoxantrone—Pharyngitis—Dactinomycin—ocular cancer	0.000123	0.0159	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EP300—ocular cancer	0.000121	0.00186	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—EP300—ocular cancer	0.000121	0.00186	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—TFDP1—ocular cancer	0.000121	0.00185	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	0.00012	0.00183	CbGpPWpGaD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ocular cancer	0.00012	0.00183	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—MDM2—ocular cancer	0.000118	0.00181	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—MDM2—ocular cancer	0.000118	0.00181	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—ocular cancer	0.000118	0.00181	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—E2F3—ocular cancer	0.000117	0.00178	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—RBBP4—ocular cancer	0.000117	0.00178	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—CDKN1B—ocular cancer	0.000115	0.00176	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—ocular cancer	0.000114	0.00175	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—RB1—ocular cancer	0.000112	0.00171	CbGpPWpGaD
Mitoxantrone—Chills—Dactinomycin—ocular cancer	0.000111	0.0144	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CDC25A—ocular cancer	0.000111	0.0017	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND3—ocular cancer	0.00011	0.00168	CbGpPWpGaD
Mitoxantrone—Alopecia—Dactinomycin—ocular cancer	0.00011	0.0142	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—MDM2—ocular cancer	0.00011	0.00167	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TFDP1—ocular cancer	0.000109	0.00166	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—CDKN1B—ocular cancer	0.000108	0.00165	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—CDKN1B—ocular cancer	0.000108	0.00165	CbGpPWpGaD
Mitoxantrone—Erythema—Dactinomycin—ocular cancer	0.000108	0.014	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—CDKN1A—ocular cancer	0.000106	0.00162	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—MYC—ocular cancer	0.000106	0.00162	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TGFB1—ocular cancer	0.000106	0.00161	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—HRAS—ocular cancer	0.000105	0.00161	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—E2F4—ocular cancer	0.000104	0.0016	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	0.000103	0.00158	CbGpPWpGaD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—ocular cancer	0.000103	0.00158	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—RBL1—ocular cancer	0.000102	0.00157	CbGpPWpGaD
Mitoxantrone—Ill-defined disorder—Dactinomycin—ocular cancer	0.0001	0.0129	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—CDKN1B—ocular cancer	0.0001	0.00153	CbGpPWpGaD
Mitoxantrone—Anaemia—Dactinomycin—ocular cancer	9.98e-05	0.0129	CcSEcCtD
Mitoxantrone—BTK—DAP12 interactions—CDKN1A—ocular cancer	9.97e-05	0.00152	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—CDKN1A—ocular cancer	9.97e-05	0.00152	CbGpPWpGaD
Mitoxantrone—CYP2E1—Tryptophan metabolism—MDM2—ocular cancer	9.89e-05	0.00151	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND3—ocular cancer	9.84e-05	0.0015	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	9.77e-05	0.00149	CbGpPWpGaD
Mitoxantrone—Malaise—Dactinomycin—ocular cancer	9.74e-05	0.0126	CcSEcCtD
Mitoxantrone—Leukopenia—Dactinomycin—ocular cancer	9.67e-05	0.0125	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—MYC—ocular cancer	9.49e-05	0.00145	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—CDK4—ocular cancer	9.38e-05	0.00143	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—AKT1—ocular cancer	9.28e-05	0.00142	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—CDKN1A—ocular cancer	9.23e-05	0.00141	CbGpPWpGaD
Mitoxantrone—Myalgia—Dactinomycin—ocular cancer	9.19e-05	0.0119	CcSEcCtD
Mitoxantrone—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ocular cancer	9.15e-05	0.0014	CbGpPWpGaD
Mitoxantrone—Discomfort—Dactinomycin—ocular cancer	9.08e-05	0.0117	CcSEcCtD
Mitoxantrone—Oedema—Dactinomycin—ocular cancer	8.81e-05	0.0114	CcSEcCtD
Mitoxantrone—Infection—Dactinomycin—ocular cancer	8.76e-05	0.0113	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDKN1B—ocular cancer	8.73e-05	0.00133	CbGpPWpGaD
Mitoxantrone—Thrombocytopenia—Dactinomycin—ocular cancer	8.63e-05	0.0112	CcSEcCtD
Mitoxantrone—Anorexia—Dactinomycin—ocular cancer	8.4e-05	0.0109	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CCND1—ocular cancer	8.33e-05	0.00127	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—ocular cancer	8.31e-05	0.00127	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—EP300—ocular cancer	8.27e-05	0.00126	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDK6—ocular cancer	8.2e-05	0.00125	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CDKN1A—ocular cancer	8.05e-05	0.00123	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Dactinomycin—ocular cancer	8.03e-05	0.0104	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—ocular cancer	7.79e-05	0.00119	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Dactinomycin—ocular cancer	7.66e-05	0.0099	CcSEcCtD
Mitoxantrone—Fatigue—Dactinomycin—ocular cancer	7.6e-05	0.00982	CcSEcCtD
Mitoxantrone—Pain—Dactinomycin—ocular cancer	7.54e-05	0.00974	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—CDK6—ocular cancer	7.33e-05	0.00112	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Dactinomycin—ocular cancer	7.26e-05	0.00938	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	7.24e-05	0.00111	CbGpPWpGaD
Mitoxantrone—Gastrointestinal pain—Dactinomycin—ocular cancer	7.21e-05	0.00931	CcSEcCtD
Mitoxantrone—ABCC1—Metabolism—PSPH—ocular cancer	7.11e-05	0.00109	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND2—ocular cancer	7.05e-05	0.00108	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—HDAC1—ocular cancer	7.05e-05	0.00108	CbGpPWpGaD
Mitoxantrone—Abdominal pain—Dactinomycin—ocular cancer	6.97e-05	0.009	CcSEcCtD
Mitoxantrone—Body temperature increased—Dactinomycin—ocular cancer	6.97e-05	0.009	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—AKT1—ocular cancer	6.96e-05	0.00106	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—HRAS—ocular cancer	6.9e-05	0.00106	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PSPH—ocular cancer	6.87e-05	0.00105	CbGpPWpGaD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—MYC—ocular cancer	6.68e-05	0.00102	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	6.61e-05	0.00101	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—HRAS—ocular cancer	6.5e-05	0.000993	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—HRAS—ocular cancer	6.5e-05	0.000993	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Dactinomycin—ocular cancer	6.49e-05	0.00839	CcSEcCtD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ocular cancer	6.46e-05	0.000988	CbGpPWpGaD
Mitoxantrone—Asthenia—Dactinomycin—ocular cancer	6.32e-05	0.00817	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN2B—ocular cancer	6.32e-05	0.000966	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	6.31e-05	0.000964	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—HDAC1—ocular cancer	6.3e-05	0.000963	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND2—ocular cancer	6.3e-05	0.000963	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PSPH—ocular cancer	6.25e-05	0.000956	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	6.1e-05	0.000933	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—AKT1—ocular cancer	6.1e-05	0.000932	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Dactinomycin—ocular cancer	6.03e-05	0.00779	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—HRAS—ocular cancer	6.01e-05	0.000919	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	5.81e-05	0.000887	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—E2F1—ocular cancer	5.8e-05	0.000886	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—AKT1—ocular cancer	5.73e-05	0.000876	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—AKT1—ocular cancer	5.73e-05	0.000876	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN2B—ocular cancer	5.65e-05	0.000864	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—SAG—ocular cancer	5.62e-05	0.000859	CbGpPWpGaD
Mitoxantrone—Vomiting—Dactinomycin—ocular cancer	5.6e-05	0.00724	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—EP300—ocular cancer	5.57e-05	0.000852	CbGpPWpGaD
Mitoxantrone—Rash—Dactinomycin—ocular cancer	5.56e-05	0.00718	CcSEcCtD
Mitoxantrone—BTK—B Cell Activation—AKT1—ocular cancer	5.31e-05	0.000811	CbGpPWpGaD
Mitoxantrone—Nausea—Dactinomycin—ocular cancer	5.24e-05	0.00676	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle—E2F1—ocular cancer	5.19e-05	0.000793	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	5.06e-05	0.000773	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	5.05e-05	0.000771	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDK2—ocular cancer	5e-05	0.000765	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—AKT1—ocular cancer	5e-05	0.000764	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—E2F5—ocular cancer	4.98e-05	0.00076	CbGpPWpGaD
Mitoxantrone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ocular cancer	4.95e-05	0.000756	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—E2F4—ocular cancer	4.87e-05	0.000745	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—RPL39—ocular cancer	4.78e-05	0.000731	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—RBL1—ocular cancer	4.78e-05	0.000731	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDK4—ocular cancer	4.73e-05	0.000723	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—MDM2—ocular cancer	4.6e-05	0.000703	CbGpPWpGaD
Mitoxantrone—CYP3A4—Tryptophan metabolism—MDM2—ocular cancer	4.59e-05	0.000701	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PSPH—ocular cancer	4.49e-05	0.000686	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDK2—ocular cancer	4.47e-05	0.000684	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—EP300—ocular cancer	4.47e-05	0.000684	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—MDM2—ocular cancer	4.42e-05	0.000675	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—ocular cancer	4.3e-05	0.000657	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDK4—ocular cancer	4.23e-05	0.000646	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CDKN1B—ocular cancer	4.2e-05	0.000642	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	4.16e-05	0.000635	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—RB1—ocular cancer	4.11e-05	0.000628	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CDKN1B—ocular cancer	4.03e-05	0.000616	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—ocular cancer	3.99e-05	0.00061	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—ocular cancer	3.95e-05	0.000603	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CDKN1A—ocular cancer	3.88e-05	0.000592	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TFDP1—ocular cancer	3.85e-05	0.000589	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CDKN1A—ocular cancer	3.72e-05	0.000569	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EP300—ocular cancer	3.69e-05	0.000564	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—RB1—ocular cancer	3.68e-05	0.000562	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	3.51e-05	0.000536	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—ocular cancer	3.4e-05	0.00052	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PSPH—ocular cancer	3.38e-05	0.000517	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—TGFB1—ocular cancer	3.37e-05	0.000515	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—ocular cancer	3.22e-05	0.000492	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN1B—ocular cancer	3.2e-05	0.000489	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MDM2—ocular cancer	3.13e-05	0.000479	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MAML2—ocular cancer	3.06e-05	0.000468	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND1—ocular cancer	3.05e-05	0.000467	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CDKN1A—ocular cancer	2.95e-05	0.000451	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN1B—ocular cancer	2.86e-05	0.000437	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—EP300—ocular cancer	2.81e-05	0.00043	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND1—ocular cancer	2.73e-05	0.000417	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—AKT1—ocular cancer	2.7e-05	0.000413	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—MDM2—ocular cancer	2.68e-05	0.000409	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CDKN1A—ocular cancer	2.64e-05	0.000404	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HRAS—ocular cancer	2.52e-05	0.000386	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—EP300—ocular cancer	2.51e-05	0.000384	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MYC—ocular cancer	2.45e-05	0.000374	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CDKN1B—ocular cancer	2.45e-05	0.000374	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HRAS—ocular cancer	2.42e-05	0.00037	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—ocular cancer	2.38e-05	0.000364	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CDKN1A—ocular cancer	2.26e-05	0.000345	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HDAC1—ocular cancer	2.24e-05	0.000342	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GNA11—ocular cancer	2.24e-05	0.000342	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—AKT1—ocular cancer	2.23e-05	0.000341	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MYC—ocular cancer	2.19e-05	0.000335	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ocular cancer	2.18e-05	0.000333	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GNA11—ocular cancer	2.16e-05	0.000331	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EP300—ocular cancer	2.15e-05	0.000328	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—AKT1—ocular cancer	2.14e-05	0.000327	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PSPH—ocular cancer	2.08e-05	0.000318	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GNAQ—ocular cancer	2.08e-05	0.000318	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ocular cancer	2.08e-05	0.000317	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GNAQ—ocular cancer	2.01e-05	0.000307	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—ocular cancer	2.01e-05	0.000307	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CDKN2B—ocular cancer	2.01e-05	0.000307	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GNA11—ocular cancer	1.97e-05	0.000301	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—ocular cancer	1.91e-05	0.000292	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GNAQ—ocular cancer	1.83e-05	0.00028	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—ocular cancer	1.8e-05	0.000275	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.68e-05	0.000256	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ocular cancer	1.67e-05	0.000255	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—ocular cancer	1.66e-05	0.000254	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—EP300—ocular cancer	1.62e-05	0.000248	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HRAS—ocular cancer	1.47e-05	0.000225	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GNA11—ocular cancer	1.41e-05	0.000216	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ocular cancer	1.37e-05	0.000209	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GNAQ—ocular cancer	1.31e-05	0.000201	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—AKT1—ocular cancer	1.3e-05	0.000198	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ocular cancer	1.16e-05	0.000177	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MDM2—ocular cancer	1.11e-05	0.00017	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GNA11—ocular cancer	1.06e-05	0.000163	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CDKN1B—ocular cancer	1.02e-05	0.000155	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GNAQ—ocular cancer	9.89e-06	0.000151	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—CDKN1A—ocular cancer	9.38e-06	0.000143	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EP300—ocular cancer	8.92e-06	0.000136	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MYC—ocular cancer	7.78e-06	0.000119	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—TGFB1—ocular cancer	7.76e-06	0.000119	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—EP300—ocular cancer	7.47e-06	0.000114	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—EP300—ocular cancer	7.23e-06	0.00011	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—EP300—ocular cancer	6.58e-06	0.0001	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GNA11—ocular cancer	6.56e-06	0.0001	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HRAS—ocular cancer	6.11e-06	9.33e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GNAQ—ocular cancer	6.1e-06	9.32e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—AKT1—ocular cancer	5.39e-06	8.24e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—EP300—ocular cancer	4.72e-06	7.22e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—AKT1—ocular cancer	4.52e-06	6.9e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—AKT1—ocular cancer	4.37e-06	6.68e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—AKT1—ocular cancer	3.97e-06	6.07e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—EP300—ocular cancer	3.56e-06	5.43e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—AKT1—ocular cancer	2.85e-06	4.36e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—EP300—ocular cancer	2.19e-06	3.35e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—AKT1—ocular cancer	2.15e-06	3.28e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—AKT1—ocular cancer	1.32e-06	2.02e-05	CbGpPWpGaD
